Agenus(US:AGEN) ZACKS·2025-05-12 13:51Core Viewpoint - Agenus reported a quarterly loss of $1.03 per share, which was better than the Zacks Consensus Estimate of a loss of $1.61, marking a significant improvement from a loss of $3.04 per share a year ago, resulting in an earnings surprise of 36.02% [1] Financial Performance - The company posted revenues of $24.07 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 14.73%, although this represents a decline from year-ago revenues of $28.01 million [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance and Outlook - Agenus shares have increased approximately 6.2% since the beginning of the year, contrasting with a decline of -3.8% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] Earnings Estimate Revisions - The trend for estimate revisions for Agenus is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$1.30 on revenues of $21.12 million, and for the current fiscal year, it is -$5.84 on revenues of $127.19 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]